Ealixir SEC Filings

Type
Report
Date
RWRW-Formular1/30/2025
S-1/AS-1/A-Formular4/25/2024
S-1/AS-1/A-Formular4/3/2024
S-1/AS-1/A-Formular2/1/2024
S-1/AS-1/A-Formular8/14/2023
15-12G15-12G-Formular10/7/2011
RWRW-Formular10/5/2011
EFFECTEFFECT-Formular10/3/2011
10KSB10KSB-Formular6/28/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/11/2007
55-Formular4/24/2007
4Insidertransaktion4/3/2007
4Insidertransaktion4/3/2007
4Insidertransaktion4/3/2007
4Insidertransaktion4/3/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/30/2007
PRE 14APRE 14A-Formular3/19/2007
SC 13G/ABeneficial ownership report2/13/2007
10QSB10QSB-Formular2/13/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/7/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/8/2007
4Insidertransaktion1/3/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/16/2006
UPLOADUPLOAD-Formular11/13/2006
10QSB10QSB-Formular11/9/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/20/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/25/2006
10QSB10QSB-Formular8/11/2006
DEF 14ADEF 14A-Formular7/26/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/18/2006
PRE 14APRE 14A-Formular7/12/2006
424B4424B4-Formular7/5/2006
EFFECTEFFECT-Formular6/30/2006
10KSB10KSB-Formular6/28/2006
4Insidertransaktion6/26/2006
4Insidertransaktion6/26/2006
S-3S-3-Formular6/19/2006
S-8S-8-Formular6/14/2006
SC 13GSC 13G-Formular6/12/2006
UPLOADUPLOAD-Formular6/8/2006
UPLOADUPLOAD-Formular6/8/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/22/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/9/2006
55-Formular4/17/2006
55-Formular4/14/2006
424B4424B4-Formular2/16/2006
10QSB10QSB-Formular2/14/2006
SC 13G/ABeneficial ownership report2/13/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/17/2006
S-3/AS-3/A-Formular1/13/2006
33-Formular1/12/2006
UPLOADUPLOAD-Formular1/6/2006
S-3S-3-Formular12/27/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/19/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/17/2005
10QSB10QSB-Formular11/9/2005
33-Formular10/19/2005
33-Formular10/19/2005
4Insidertransaktion4/30/2004
10KSB10KSB-Formular6/29/2000
424B3424B3-Formular6/26/2000
424B3424B3-Formular6/14/2000
424B3424B3-Formular5/16/2000
424B3424B3-Formular5/10/2000
S-3/AS-3/A-Formular5/1/2000
S-3S-3-Formular4/21/2000
424B3424B3-Formular4/5/2000
SC 13D/ASC 13D/A-Formular3/24/2000
424B3424B3-Formular3/21/2000
S-3/AS-3/A-Formular3/17/2000
SC 13D/ASC 13D/A-Formular3/10/2000
424B3424B3-Formular3/9/2000
S-3S-3-Formular3/8/2000
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/17/2000
10QSB10QSB-Formular2/14/2000
SC 13G/ABeneficial ownership report2/1/2000

Ealixir Documents 2026

This page contains all official documents and SEC filings for Ealixir stock (EAXR, ISIN: US27005B1035). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 76 documents are available. Data is updated regularly to provide investors with a complete overview of Ealixir's regulatory filings.

Ealixir Stock analysis

Ealixir Ealixir Inc is a biotechnology company founded in 2012 by Dr. Nithin Rajan. Dr. Rajan earned his doctoral degree in biomedical science from the University of Ottawa and has over ten years of experience in the field of biomedical research. Ealixir Inc is an innovative firm specializing in the development of novel therapeutic technologies based on cell and proteomic research. Ealixir's goal is to help patients with serious or chronic illnesses by offering biological solutions that support the body's natural functions. Ealixir has developed the concept of "lifestyle medicine," aiming to develop treatments that not only combat diseases but also influence the patient's lifestyle to help them lead a healthier life. The company follows an integrative approach, combining the use of medications and other therapeutic approaches. Ealixir specializes in ingredients and technologies that have the potential to stimulate and activate the body to promote natural regenerative processes. One of Ealixir's significant products is the Arthritin system, which is used for the treatment of arthritis and pain. Arthritin utilizes a blend of pain relief, inflammation inhibitors, and regeneration promoters to effectively alleviate arthritis pain and reverse the damage caused by the disease to the joints. Ealixir is also a pioneer in the development of nano "in-minutes" technologies, where nanoparticles are used to actively transport active substances to specific target cells, thereby achieving results in minutes rather than hours. Another important product of Ealixir is Collagenix, a beauty product that uses a blend of collagen, vitamins, and minerals to improve skin structure and wrinkle depth. Ealixir also offers products for animal care and medicine. The company has developed a new product for wound care in pets using the Ealixir technology. The solution consists of antibacterial ingredients and promotes the growth of new tissue. Ealixir also focuses on researching dietary supplements that contribute to overall health and well-being. The company pays special attention to proteins, magnesium, and omega-3 fatty acids. The range includes CBD oil and support for restful sleep. Overall, Ealixir has established itself as a leading company in biomedical research and the development of innovative therapies. The company's products are at the forefront of technology and are developed and tested by a great team of researchers and scientists. The brand has experienced rapid growth in recent years and will undoubtedly achieve many successes in the future, benefiting both patients and animal lovers as well as people who value health and wellness.